Creative Biomart Blog

Mon, 2024/07/01

MSD PD-1 Inhibitor Approved By FDA for First-Line Treatment of Advanced Cancer

Keytruda is a PD-1 inhibitor developed by Merck, which can block the interaction between PD-1 and its ligands PD-L1 and PD-L2, release immune suppression mediated by the PD-1 signaling pathway, activate T lymphocytes that may affect tumor cells and healthy cells, and enhance the human immune system's ability to detect and eliminate cancer cells. Since obtaining FDA approval for the treatment of advanced melanoma for the first time in 2014, Keytruda has received FDA approval for the treatment of at least 16 types of cancer, as well as indications for unlimited cancer types. Our Featured Prod

Tue, 2024/06/11

Commonly Used Cholesterol Lowering Drugs, Statins, Can Prevent Cancer

Researchers from Harvard Medical School and Massachusetts General Hospital published a research paper in the journal Nature Communications titled: Statin prevents cancer development in chronic inflammation by blocking interleukin 33 expression. This study suggests that commonly used cholesterol-lowering drugs such as statins can prevent the progression of chronic inflammation to cancer by blocking the expression of interleukin-33 (IL-33). Our Related Proteins Cat. No. Product Name Species Source Tag IL33-122H Active Recombinant Human Interleukin 33, HIgG1 Fc-tagged, mutant Human CHO F

Tue, 2024/06/11

Liver ACOX1 Regulates Circulating Lipid Levels and Promotes Metabolic Health through Fat Remodeling

Obesity is a serious public health problem, which is related to a wide range of complications, including type 2 diabetes, cardiovascular disease, and liver steatosis. Dysfunction of lipid metabolism is a hallmark of obesity, related to the pathogenesis of these comorbidities. The imbalance between lipid synthesis and degradation leads to the accumulation of excess fat in adipose tissue and other organs. Brown adipose tissue (BAT) or related beige adipose tissue is an induced form of adipocytes produced by subcutaneous white adipose tissue (WAT) under certain external stimuli. Therapeutic ex

Tue, 2024/06/11

A Novel Therapy for Alzheimer's disease Targeting Neuronal Calcium Homeostasis

A new study published in the journal Science has brought us a new approach to the treatment of Alzheimer's disease (AD). Unlike many previous approaches to new drug development, this therapy does not target the key pathological proteins of Alzheimer's disease, beta-amyloid (Aβ) or tau protein, but rather targets the more fundamental neuronal calcium homeostasis. Calcium ion disorders play an important pathological role in various types of dementia, including AD. In the preclinical stage of the disease, calcium ion disorders have persisted and directly led to synaptic loss, which is a key pa

Tue, 2024/06/11

CRL3 May Have the Potential to Lower Blood Sugar Levels in the Body

Cullin RING E3 ligase (CRL) has become a key regulator of disease modification pathways and therapeutic targets. CRL (CRL3) containing Cullin 3 (Cul3) is involved in regulating liver insulin and oxidative stress signaling. However, the function of CRL3 in liver pathophysiology is currently unclear. Recently, a research report titled "Cullin 3 RING E3 ligase inactivation causes NRF2-dependent NADH reductive stress, hepatic lipodystrophy, and systemic insulin resistance" was published in the journal Proceedings of the National Academy of Sciences. Scientists from institutions such as the Univ

Tue, 2024/06/11

Targeting SOX13 to Overcome Iron Death Resistance in Gastric Cancer

Gastric cancer (GC) is the fifth most common cancer and the fourth leading cause of cancer-related deaths in the world. Despite significant progress in gastric cancer management, the prognosis of patients with advanced gastric cancer remains poor. Cisplatin-based chemotherapy is still the first-line adjuvant or neoadjuvant treatment for advanced gastric cancer, but understanding chemotherapy resistance remains a barrier to clinical efficacy. Cancer immunotherapy, including immune checkpoint inhibitors, has become an effective treatment for various types of cancer. However, due to drug resistan

Tue, 2024/06/11

A New Strategy For Tumor Growth Inhibition: BCL9/BCL9L Targeted Therapy And cDC1 Activation

Zhu Di and Wang Mingwei from Fudan University jointly published a research paper titled "Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration" in Signal Transmission and Targeted Therapy. This study indicates that targeting BCL9/BCL9L enhances antigen presentation by stimulating cDC1 activation and infiltration into tumors. Knockout mice with novel inhibitors hsBCL9z96 or BCL9/BCL9L can significantly delay tumor growth and promote anti-tumor CD8+T cell response by inhibiting BCL9/BCL9L. Mechanistically, t

Tue, 2024/06/11

Topological Generation Pathways of Multiple Transmembrane Proteins

More than half of the approximately 5000 membrane proteins synthesized on the endoplasmic reticulum membrane of human cells are multi-transmembrane proteins. Multiple transmembrane proteins play important roles in cells as ion channels, transporters, receptor proteins, transmembrane enzymes, and more. These functions rely heavily on the polarity and charged amino acids of the transmembrane domain, and the polar and charged amino acid side chains typically exhibit lipid-repellent properties, resulting in lower hydrophobicity of the transmembrane helix (TMH) they are located in. Statistics show